Citrulline Allo. Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children

Benign Disease Clinical Trial

Official title: Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children

Status Recruiting

Clinical Trial Summary

determine the interest of the dosage of citrullinemia to monitor the bowel damage after allogeneic bone marrow transplantation in children.

Clinical Trial Description

30 children included. Dosage of citrullinemia on day -7, day 0 and every week up to 100 days after BMT. Histological examination and extensive infectious screening in case of persistent digestive symptoms (more than 3 days).

Two groups of patients regarding on digestive involvement. Comparison of the values of citrullinemia between these two groups. ;

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Benign Disease
• Citrullinemia

• NCT number: NCT00751452
• Study type: Observational
• Source: University Hospital, Clermont-Ferrand
• Contact: Lacarin Patrick
• Email: placarin@chu-clermontferrand.fr
• Status: Recruiting
• Phase: N/A
• Start date: April 2008
• Completion date: September 2009